Full Press Release Details
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide as First ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC PCSK1 or LEPR Defic.
RYTM
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide as First ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC PCSK1 or LEPR Defic
Key Takeaway: Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide as First ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC PCSK1 or LEPR Defic